On-body injector for CD38 mAb administration in NDMM
Join Prof. Mohamad Mohty and Dr. Noopur Raje, two leading experts, as they discuss the evolving treatment landscape in multiple myeloma — from quadruplet regimens for non-transplant eligible patients to the transformative potential of on-body injector technology and the future of home-based, decentralized care.
Supported by

Cure
Join Prof. Mohamad Mohty and Dr María-Victoria Mateos, two leading experts, as they explore the emerging concept of cure in multiple myeloma — from the consensus definition of MRD-based cure and the role of anti-CD38 therapies in newly diagnosed patients, to the curative potential of CAR T-cell therapy at first relapse and the future of trispecific antibodies and treatment-free remission.






























